TY - JOUR
T1 - The Impact of Paratracheal Lymphadenectomy on Survival After Esophagectomy
T2 - A Nationwide Propensity Score Matched Analysis
AU - Hagens, Eliza R C
AU - Kingma, B Feike
AU - van Berge Henegouwen, Mark I
AU - Borggreve, Alicia S
AU - Ruurda, Jelle P
AU - van Hillegersberg, Richard
AU - Gisbertz, Suzanne S
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/3/5
Y1 - 2025/3/5
N2 -
Purpose: To investigate the impact of paratracheal lymphadenectomy on survival in patients undergoing an esophagectomy for cancer. The secondary objective was to assess the effect on short-term outcomes.
Methods: Between 2011-2017, patients with an esophageal or gastroesophageal junction carcinoma treated with elective transthoracic esophagectomy with two-field lymphadenectomy were included from the Dutch Upper Gastro-intestinal Cancer Audit registry. After 1:1 propensity score matching of patients with and without paratracheal lymphadenectomy within histologic subgroups, short-term outcomes and overall survival were compared between the two groups.
Results: A total of 1154 patients with adenocarcinoma and 294 patients with squamous cell carcinoma were matched. Lymph node yield was significantly higher (22 versus 19 nodes,
p < 0.001) in patients with paratracheal lymphadenectomy for both tumor types. Paratracheal lymphadenectomy was associated with more recurrent laryngeal nerve injury (10% versus 5%,
p = 0.002) and chylothorax in patients with adenocarcinoma (10% versus 5%,
p = 0.010) and with more anastomotic leakage in patients with squamous cell carcinoma (42% versus 27%,
p = 0.014). The 3- and 5-year survival in patients with and without a paratracheal lymphadenectomy were for adenocarcinoma, respectively, 58% versus 56% and 48% in both groups (log rank:
p = 0.578) and for patients with a squamous cell carcinoma, 62% in both groups and 57% versus 54% (log rank:
p = 0.668).
Conclusions: The addition of paratracheal lymphadenectomy significantly increases lymph node yield in transthoracic esophagectomy but did not result in improved survival for esophageal cancer patients in the current dataset. However, there was an increase in postoperative morbidity in patients who underwent a paratracheal lymphadenectomy.
AB -
Purpose: To investigate the impact of paratracheal lymphadenectomy on survival in patients undergoing an esophagectomy for cancer. The secondary objective was to assess the effect on short-term outcomes.
Methods: Between 2011-2017, patients with an esophageal or gastroesophageal junction carcinoma treated with elective transthoracic esophagectomy with two-field lymphadenectomy were included from the Dutch Upper Gastro-intestinal Cancer Audit registry. After 1:1 propensity score matching of patients with and without paratracheal lymphadenectomy within histologic subgroups, short-term outcomes and overall survival were compared between the two groups.
Results: A total of 1154 patients with adenocarcinoma and 294 patients with squamous cell carcinoma were matched. Lymph node yield was significantly higher (22 versus 19 nodes,
p < 0.001) in patients with paratracheal lymphadenectomy for both tumor types. Paratracheal lymphadenectomy was associated with more recurrent laryngeal nerve injury (10% versus 5%,
p = 0.002) and chylothorax in patients with adenocarcinoma (10% versus 5%,
p = 0.010) and with more anastomotic leakage in patients with squamous cell carcinoma (42% versus 27%,
p = 0.014). The 3- and 5-year survival in patients with and without a paratracheal lymphadenectomy were for adenocarcinoma, respectively, 58% versus 56% and 48% in both groups (log rank:
p = 0.578) and for patients with a squamous cell carcinoma, 62% in both groups and 57% versus 54% (log rank:
p = 0.668).
Conclusions: The addition of paratracheal lymphadenectomy significantly increases lymph node yield in transthoracic esophagectomy but did not result in improved survival for esophageal cancer patients in the current dataset. However, there was an increase in postoperative morbidity in patients who underwent a paratracheal lymphadenectomy.
U2 - 10.3390/cancers17050888
DO - 10.3390/cancers17050888
M3 - Article
C2 - 40075734
SN - 2072-6694
VL - 17
JO - Cancers
JF - Cancers
IS - 5
M1 - 888
ER -